- Home
- OKYO vs IMUX Comparison
OKYO vs IMUX Comparison
Compare OKYO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- IMUX
- Stock Information
- Founded
- OKYO 2007
- IMUX 2016
- Country
- OKYO United Kingdom
- IMUX United States
- Employees
- OKYO N/A
- IMUX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- IMUX Health Care
- Exchange
- OKYO Nasdaq
- IMUX Nasdaq
- Market Cap
- OKYO 85.0M
- IMUX 90.4M
- IPO Year
- OKYO 2022
- IMUX N/A
- Fundamental
- Price
- OKYO $2.11
- IMUX $0.84
- Analyst Decision
- OKYO Strong Buy
- IMUX Strong Buy
- Analyst Count
- OKYO 1
- IMUX 5
- Target Price
- OKYO $7.00
- IMUX $7.50
- AVG Volume (30 Days)
- OKYO 56.1K
- IMUX 1.3M
- Earning Date
- OKYO 07-18-2025
- IMUX 11-06-2025
- Dividend Yield
- OKYO N/A
- IMUX N/A
- EPS Growth
- OKYO N/A
- IMUX N/A
- EPS
- OKYO N/A
- IMUX N/A
- Revenue
- OKYO N/A
- IMUX N/A
- Revenue This Year
- OKYO N/A
- IMUX N/A
- Revenue Next Year
- OKYO N/A
- IMUX N/A
- P/E Ratio
- OKYO N/A
- IMUX N/A
- Revenue Growth
- OKYO N/A
- IMUX N/A
- 52 Week Low
- OKYO $0.90
- IMUX $0.56
- 52 Week High
- OKYO $3.35
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- OKYO 35.10
- IMUX 49.36
- Support Level
- OKYO $2.06
- IMUX $0.75
- Resistance Level
- OKYO $2.17
- IMUX $0.90
- Average True Range (ATR)
- OKYO 0.14
- IMUX 0.06
- MACD
- OKYO -0.00
- IMUX 0.00
- Stochastic Oscillator
- OKYO 12.50
- IMUX 65.16
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.